The outcome and biocompatibility of HER2-based CAR-T therapy have been investigated in trials in HER2-positive sarcoma, and dose-limiting toxicity has not been observed.352–354 Although it is expressed at a lower level, HER2 can also be efficiently recognized by CAR-T lymphocytes, suggesting that CAR-T cells have great potential to target cancer cells. The gene discussed is ERBB2; the disease is sarcoma.